ArticleTherapeutic advances in medical oncology2015
Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base.
Article in Therapeutic advances in medical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Disparities in Access to Oncologic Care in Pancreatic Cancer: A Systematic Review.Annals of surgical oncology · 2022Pooled it
- Investigation of Treatment-Related Disparities in Metastatic Pancreatic Cancer Patients Using Real-World Data.Cancer medicine · 2025Article
- The impact of metastatic sites on survival Rates and predictors of extended survival in patients with metastatic pancreatic cancer.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2024Article
- Article
- Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States.Journal of the National Cancer Institute · 2022Article
- Costs by Site of Service for Commercially-Insured Patients with Metastatic Pancreatic Cancer Receiving Guideline-Recommended Chemotherapy: Comparing Community Oncology and Hospital Outpatient Settings.ClinicoEconomics and outcomes research : CEOR · 2022Article
- Do-Not-Resuscitate Orders and Outcomes for Patients with Pancreatic Cancer.Journal of pancreatic cancer · 2022Article
- Sex-Related Differences in Outcomes for Oropharyngeal Squamous Cell Carcinoma by HPV Status.International journal of otolaryngology · 2022Article
- Article
- Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes.Cancer medicine · 2020Article
- Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000-2013.Medicine · 2019Observational
- Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma: a population-based analysis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2019Article
- HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients.OncoTargets and therapy · 2019Article
- Disparities in Pancreatic Cancer Treatment and Outcomes.Health equity · 2019Review
- SPECIFIC MOLECULAR RECOGNITION AS A STRATEGY TO DELINEATE TUMOR MARGIN USING TOPICALLY APPLIED FLUORESCENCE EMBEDDED NANOPARTICLES.Precision nanomedicine · 2018Article
- Sex disparities in use of chemotherapy and survival in patients with advanced bladder cancer.Cancer · 2016Article
- Sex Differences in Head and Neck Carcinoma - A Retrospective Study on 1115 Head and Neck Carcinoma Patients in Austria.Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-facialeArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer accounts for approximately 7% of all cancer deaths. More than half of all pancreatic cancers are stage IV at diagnosis, where systemic chemotherapy is used with the goal of life prolongation as well as palliation. The patient characteristics and health system factors that drive the use of systemic therapy are unknown.
methodThis is a retrospective study of stage IV pancreatic cancer patients (n = 140,210) diagnosed between 2000 and 2011 in the NCDB. NCDB contains approximately 70% of new cancer diagnosis from more than 1500 accredited cancer programs in the United States and Puerto Rico. Chi-squared test was used to determine any differences in characteristics of patients who did or did not receive systemic therapy.
resultsOur study demonstrated that only 49.1% of stage IV pancreatic cancer patients received systemic therapy. The use of systemic therapy is significantly lower in female, African American/Hispanic, patients older than 40 years, those without insurance or with Medicare and Medicaid, higher Charlson Comorbidity Score, poor economic and educational status and in nonacademic centers.
conclusionsThis is the largest study to evaluate the determinants of systemic therapy use in stage IV pancreatic cancer. The use of systemic therapy was significantly lower in patients older than 40 years, lower educational status, nonprivate insurance and with higher Charlson Comorbidity Scores. In addition, the use of systemic therapy was lower with female sex, African Americans/Hispanic, and lower socio-economic status. Understanding the barriers in the use of systemic therapy as well as appropriate utilization of systemic therapy can both optimize cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.